Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Hoang

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Nature Reviews. Urology|October 6, 2011
Prolactin regulation of the prostate gland: a female player in a male gameVincent Goffin, David T Hoang, Roman L Bogorad, et al.
Oncotarget|October 15, 2016
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple anglesDavid T Hoang, Kenneth A Iczkowski, Deepak Kilari, et al.
Endocrine-Related Cancer|September 10, 2011
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancerMatthew J Schiewer, Robert Den, David T Hoang, et al.
Molecular Cancer Therapeutics|March 1, 2014
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formationLei Gu, Pooja Talati, Paraskevi Vogiatzi, et al.
Molecular Cancer Therapeutics|September 25, 2019
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 InhibitorsVindhya Udhane, Cristina Maranto, David T Hoang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2018
STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA RepairCristina Maranto, Vindhya Udhane, David T Hoang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2013
Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancerLei Gu, Zhiyong Liao, David T Hoang, et al.
Molecular Cancer Therapeutics|January 2, 2015
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate CancerDavid T Hoang, Lei Gu, Zhiyong Liao, et al.
The American Journal of Pathology|September 13, 2015
Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate CancerPooja G Talati, Lei Gu, Elyse M Ellsworth, et al.
The American Journal of Pathology|May 11, 2013
STAT5A/B gene locus undergoes amplification during human prostate cancer progressionBassem R Haddad, Lei Gu, Tuomas Mirtti, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Nature Reviews. Urology|October 6, 2011
Prolactin regulation of the prostate gland: a female player in a male gameVincent Goffin, David T Hoang, Roman L Bogorad, et al.
Oncotarget|October 15, 2016
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple anglesDavid T Hoang, Kenneth A Iczkowski, Deepak Kilari, et al.
Endocrine-Related Cancer|September 10, 2011
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancerMatthew J Schiewer, Robert Den, David T Hoang, et al.
Molecular Cancer Therapeutics|March 1, 2014
Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formationLei Gu, Pooja Talati, Paraskevi Vogiatzi, et al.
Molecular Cancer Therapeutics|September 25, 2019
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 InhibitorsVindhya Udhane, Cristina Maranto, David T Hoang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2018
STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA RepairCristina Maranto, Vindhya Udhane, David T Hoang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2013
Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancerLei Gu, Zhiyong Liao, David T Hoang, et al.
Molecular Cancer Therapeutics|January 2, 2015
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate CancerDavid T Hoang, Lei Gu, Zhiyong Liao, et al.
The American Journal of Pathology|September 13, 2015
Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate CancerPooja G Talati, Lei Gu, Elyse M Ellsworth, et al.
The American Journal of Pathology|May 11, 2013
STAT5A/B gene locus undergoes amplification during human prostate cancer progressionBassem R Haddad, Lei Gu, Tuomas Mirtti, et al.
Pageof 2